ReviewCellular oncology (Dordrecht, Netherlands)2015
Intrinsic cancer subtypes--next steps into personalized medicine.
Review in Cellular oncology (Dordrecht, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects.Nature communications · 2018Trial
- Utilizing Feature Selection Techniques for AI-Driven Tumor Subtype Classification: Enhancing Precision in Cancer Diagnostics.Biomolecules · 2025Review
- Anticancer Activity of Benzo[Cells · 2024Article
- Simple and Scalable Algorithms for Cluster-Aware Precision Medicine.Proceedings of machine learning research · 2024Article
- Article
- Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer.Cancers · 2021Review
- Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer.Frontiers in immunology · 2021Review
- Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment?Visceral medicine · 2019Review
- Age-associated prognostic and predictive biomarkers in patients with breast cancer.Oncology letters · 2017Article
- Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.Cellular oncology (Dordrecht, Netherlands) · 2017Review
- Significant Prognostic Features and Patterns of SomaticCancer informatics · 2017Article
- Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells.Oncotarget · 2016Article
- Novel multifunctional pH-sensitive nanoparticles loaded into microbubbles as drug delivery vehicles for enhanced tumor targeting.Scientific reports · 2016Article
- Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.Molecular pharmaceutics · 2016Article
- ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation.Oncotarget · 2016Article
- Behavioral, perceptual, and neural alterations in sensory and multisensory function in autism spectrum disorder.Progress in neurobiology · 2015Review
- Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid.Cellular oncology (Dordrecht, Netherlands) · 2015Article
- Update of genetic susceptibility in patients with Kawasaki disease.Korean journal of pediatrics · 2015Review
- Personalized cancer medicine: next steps in the genomic era.Cellular oncology (Dordrecht, Netherlands) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent technological advances have significantly improved our understanding of tumor biology by means of high-throughput mutation and transcriptome analyses. The application of genomics has revealed the mutational landscape and the specific deregulated pathways in different tumor types. At a transcriptional level, multiple gene expression signatures have been developed to identify biologically distinct subgroups of tumors. By supervised analysis, several prognostic signatures have been generated, some of them being commercially available. However, an unsupervised approach is required to discover a priori unknown molecular subtypes, the so-called intrinsic subtypes. Moreover, an integrative analysis of the molecular events associated with tumor biology has been translated into a better tumor classification. This molecular characterization confers new opportunities for therapeutic strategies in the management of cancer patients. However, the applicability of these new molecular classifications is limited because of several issues such as technological validation and cost. Further comparison with well-established clinical and pathological features is expected to accelerate clinical translation. In this review, we will focus on the data reported on molecular classification in the most common tumor types such as breast, colorectal and lung carcinoma, with special emphasis on recent data regarding tumor intrinsic subtypes. Likewise, we will review the potential applicability of these new classifications in the clinical routine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.